These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32555695)

  • 21. Effect of Combination l-Citrulline and Metformin Treatment on Motor Function in Patients With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
    Hafner P; Bonati U; Klein A; Rubino D; Gocheva V; Schmidt S; Schroeder J; Bernert G; Laugel V; Steinlin M; Capone A; Gloor M; Bieri O; Hemkens LG; Speich B; Zumbrunn T; Gueven N; Fischer D
    JAMA Netw Open; 2019 Oct; 2(10):e1914171. PubMed ID: 31664444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Boys With Duchenne Muscular Dystrophy: 1-Year Locomotor Changes in Relation to a Control Group.
    Martini J; Caromano FA; Carvalho EV; Goya PA; Hayasaka RM; Nakazune S; Fávero FM; Voos MC
    Percept Mot Skills; 2018 Feb; 125(1):40-56. PubMed ID: 29171337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials.
    McDonald CM; Sajeev G; Yao Z; McDonnell E; Elfring G; Souza M; Peltz SW; Darras BT; Shieh PB; Cox DA; Landry J; Signorovitch J;
    Muscle Nerve; 2020 Jan; 61(1):26-35. PubMed ID: 31599456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy.
    McDonald CM; Henricson EK; Han JJ; Abresch RT; Nicorici A; Elfring GL; Atkinson L; Reha A; Hirawat S; Miller LL
    Muscle Nerve; 2010 Apr; 41(4):500-10. PubMed ID: 19941337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    McDonald CM; Campbell C; Torricelli RE; Finkel RS; Flanigan KM; Goemans N; Heydemann P; Kaminska A; Kirschner J; Muntoni F; Osorio AN; Schara U; Sejersen T; Shieh PB; Sweeney HL; Topaloglu H; Tulinius M; Vilchez JJ; Voit T; Wong B; Elfring G; Kroger H; Luo X; McIntosh J; Ong T; Riebling P; Souza M; Spiegel RJ; Peltz SW; Mercuri E; ;
    Lancet; 2017 Sep; 390(10101):1489-1498. PubMed ID: 28728956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanographic analysis of the timed 4 stair climb test - methodology and reference data of healthy children and adolescents.
    Schorling DC; Rawer R; Kuhlmann I; Müller C; Pechmann A; Kirschner J
    J Musculoskelet Neuronal Interact; 2023 Mar; 23(1):4-25. PubMed ID: 36856096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Longitudinal timed function tests in Duchenne muscular dystrophy: ImagingDMD cohort natural history.
    Arora H; Willcocks RJ; Lott DJ; Harrington AT; Senesac CR; Zilke KL; Daniels MJ; Xu D; Tennekoon GI; Finanger EL; Russman BS; Finkel RS; Triplett WT; Byrne BJ; Walter GA; Sweeney HL; Vandenborne K
    Muscle Nerve; 2018 Nov; 58(5):631-638. PubMed ID: 29742798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative muscle MRI biomarkers in Duchenne muscular dystrophy: cross-sectional correlations with age and functional tests.
    Sherlock SP; Zhang Y; Binks M; Marraffino S
    Biomark Med; 2021 Jun; 15(10):761-773. PubMed ID: 34155911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials.
    Ricotti V; Ridout DA; Pane M; Main M; Mayhew A; Mercuri E; Manzur AY; Muntoni F;
    J Neurol Neurosurg Psychiatry; 2016 Feb; 87(2):149-55. PubMed ID: 25733532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modeling Early Heterogeneous Rates of Progression in Boys with Duchenne Muscular Dystrophy.
    Fang Y; McDonald CM; Clemens PR; Gordish HD; Illei K; Hoffman EP; ; Dang UJ
    J Neuromuscul Dis; 2023; 10(3):349-364. PubMed ID: 36806514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Electrical impedance myography for reducing sample size in Duchenne muscular dystrophy trials.
    Leitner ML; Kapur K; Darras BT; Yang M; Wong B; Dalle Pazze L; Florence J; Buck M; Freedman L; Bohorquez J; Rutkove S; Zaidman C
    Ann Clin Transl Neurol; 2020 Jan; 7(1):4-14. PubMed ID: 31876124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lower Extremity Functional Outcome Measures in Duchenne Muscular Dystrophy-A Delphi Survey.
    Senesac CR; Lott DJ; Willcocks RJ; Duong T; Smith BK
    J Neuromuscul Dis; 2019; 6(1):75-83. PubMed ID: 30562905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial.
    Beenakker EA; Fock JM; Van Tol MJ; Maurits NM; Koopman HM; Brouwer OF; Van der Hoeven JH
    Arch Neurol; 2005 Jan; 62(1):128-32. PubMed ID: 15642859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a model-based clinical trial simulation platform to optimize the design of clinical trials for Duchenne muscular dystrophy.
    Lingineni K; Aggarwal V; Morales JF; Conrado DJ; Corey D; Vong C; Burton J; Larkindale J; Romero K; Schmidt S; Kim S;
    CPT Pharmacometrics Syst Pharmacol; 2022 Mar; 11(3):318-332. PubMed ID: 34877803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy.
    Mazzone E; Martinelli D; Berardinelli A; Messina S; D'Amico A; Vasco G; Main M; Doglio L; Politano L; Cavallaro F; Frosini S; Bello L; Carlesi A; Bonetti AM; Zucchini E; De Sanctis R; Scutifero M; Bianco F; Rossi F; Motta MC; Sacco A; Donati MA; Mongini T; Pini A; Battini R; Pegoraro E; Pane M; Pasquini E; Bruno C; Vita G; de Waure C; Bertini E; Mercuri E
    Neuromuscul Disord; 2010 Nov; 20(11):712-6. PubMed ID: 20634072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of gait in Duchenne Muscular Dystrophy: Relation of 3D gait analysis to clinical assessment.
    Romano A; Favetta M; Schirinzi T; Summa S; Minosse S; D'Amico A; Catteruccia M; Petrarca M; Castelli E; Bertini E; Vasco G
    Neuromuscul Disord; 2019 Dec; 29(12):920-929. PubMed ID: 31791868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual-energy X-ray absorptiometry measures of lean body mass as a biomarker for progression in boys with Duchenne muscular dystrophy.
    Sherlock SP; Palmer J; Wagner KR; Abdel-Hamid HZ; Tian C; Mah JK; Muntoni F; Guglieri M; Butterfield RJ; Charnas L; Marraffino S
    Sci Rep; 2022 Nov; 12(1):18762. PubMed ID: 36335191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Longitudinal natural history in young boys with Duchenne muscular dystrophy.
    Coratti G; Brogna C; Norcia G; Ricotti V; Abbott L; D'Amico A; Berardinelli A; Vita GL; Lucibello S; Messina S; Sansone V; Albamonte E; Colia G; Salmin F; Gardani A; Manzur A; Main M; Baranello G; Arnoldi MT; Parsons J; Carry T; Connolly AM; Bertini E; Muntoni F; Pane M; Mercuri E
    Neuromuscul Disord; 2019 Nov; 29(11):857-862. PubMed ID: 31629611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study.
    McDonald CM; Henricson EK; Abresch RT; Florence J; Eagle M; Gappmaier E; Glanzman AM; ; Spiegel R; Barth J; Elfring G; Reha A; Peltz SW
    Muscle Nerve; 2013 Sep; 48(3):357-68. PubMed ID: 23674289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy.
    Nagy S; Schmidt S; Hafner P; Klein A; Rubino-Nacht D; Gocheva V; Bieri O; Vuillerot C; Bonati U; Fischer D
    J Vis Exp; 2019 Jan; (143):. PubMed ID: 30688316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.